Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O’Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM (2019) NCCN guidelines insights: ovarian cancer, version 1.2019. J Natl Compr Canc Netw 17(8):896–909. https://doi.org/10.6004/jnccn.2019.0039

Article  CAS  PubMed  Google Scholar 

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, Gonzalez-Martin A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505. https://doi.org/10.1056/NEJMoa1810858

Article  CAS  PubMed  Google Scholar 

Gonzalez-Martin A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Perez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, Investigators PE-OG- (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391–2402. https://doi.org/10.1056/NEJMoa1910962

Article  CAS  PubMed  Google Scholar 

Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950–1955. https://doi.org/10.1056/NEJM199612263352603

Article  CAS  PubMed  Google Scholar 

Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19(4):1001–1007. https://doi.org/10.1200/JCO.2001.19.4.1001

Article  CAS  PubMed  Google Scholar 

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology G (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43. https://doi.org/10.1056/NEJMoa052985

Article  CAS  PubMed  Google Scholar 

Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS (2019) Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study. J Clin Oncol 37(16):1380–1390. https://doi.org/10.1200/JCO.18.01568

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 100(1):27–32. https://doi.org/10.1016/j.ygyno.2005.11.013

Article  PubMed  Google Scholar 

Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43(3):1426–1431

CAS  PubMed  Google Scholar 

Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF (1985) Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 20(1):1–9. https://doi.org/10.1016/0090-8258(85)90118-0

Article  CAS  PubMed  Google Scholar 

Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M et al (1992) Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study. J Clin Oncol 10(9):1485–1491. https://doi.org/10.1200/JCO.1992.10.9.1485

Article  CAS  PubMed  Google Scholar 

Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study. J Clin Oncol 13(12):2961–2967. https://doi.org/10.1200/JCO.1995.13.12.2961

Article  CAS  PubMed  Google Scholar 

LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18(2):184–191

Article  CAS  PubMed  Google Scholar 

Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JH, Beijnen JH (2011) A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879(28):2984–2990. https://doi.org/10.1016/j.jchromb.2011.08.034

Article  CAS  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events v5.0 (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf. Accessed 2 Aug 2021

Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G, Verweij J (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73(12):1569–1575. https://doi.org/10.1038/bjc.1996.296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fournier C, Vennin P, Hecquet B (1988) Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 21(1):75–77. https://doi.org/10.1007/BF00262745

Article  CAS  PubMed  Google Scholar 

Hecquet B, Vennin P, Fournier C, Poissonnier B (1987) Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer. Cancer Res 47(22):6134–6137

CAS  PubMed  Google Scholar 

Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, Pinedo HM (1982) Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol 18(11):1069–1074. https://doi.org/10.1016/0277-5379(82)90085-2

Article  CAS  PubMed  Google Scholar 

Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39(2):136–144. https://doi.org/10.1038/clpt.1986.24

Article  CAS  PubMed  Google Scholar 

Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F, Aoki D (2020) Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep 10(1):12581. https://doi.org/10.1038/s41598-020-69488-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437. https://doi.org/10.3322/caac.21204

Article  PubMed  Google Scholar 

Romano A, Capozza MA, Mastrangelo S, Maurizi P, Triarico S, Rolesi R, Attina G, Fetoni AR, Ruggiero A (2020) Assessment and management of platinum-related ototoxicity in children treated for cancer. Cancers (Basel). https://doi.org/10.3390/cancers12051266

Article  PubMed  Google Scholar 

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A (2002) Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 8(4):1237–1241

CAS  PubMed  Google Scholar 

Helson L, Helson C, Malik S, Ainsworth S, Mangiardi J (1993) A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs 4(4):487–490. https://doi.org/10.1097/00001813-199308000-00010

Article  CAS  PubMed  Google Scholar 

Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609–621. https://doi.org/10.1517/14740338.6.5.609

Article  CAS  PubMed  Google Scholar 

Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O’Malley DM (2015) Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 33(26):2841–2847. https://doi.org/10.1200/JCO.2015.61.4776

Article  CAS  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif